Table 1. Detection of tumor-derived DNA in saliva and plasma.

The percentages of patients whose tumors were detectable through the examination of saliva, plasma, or both are shown, grouped by tumor site, stage, and HPV status.

	Saliva, % with mutations (95% confidence intervals) (total number studied)	Plasma, % with mutations (95% confidence intervals) (total number studied)	Saliva or plasma, % with mutations (95% confidence intervals) (total number studied)*
Site
Oral cavity	100 (92–100%) (46)	80 (52–96%) (15)	100 (78–100%) (15)
Oropharynx	47 (30–65%) (34)	91 (71–99%) (22)	91 (71–99%) (22)
Larynx	70 (35–93%) (10)	86 (42–99%) (7)	100 (59–100%) (7)
Hypopharynx	67 (9.4–99%) (3)	100 (29–100%) (3)	100 (29–100%) (3)
Stage
Early (I and II)	100 (83–100%) (20)	70 (35–93%) (10)	100 (69–100%) (10)
Late (III and IV)	70 (58–80%) (73)	92 (78–98%) (37)	95 (82–99%) (37)
HPV
Positive	40 (23–59%) (30)	86 (64–97%) (21)	86 (64–97%) (21)
Total	76 (66–85%) (93)	87 (74–95%) (47)	96 (85–99%) (47)

^*Includes only patients from whom both saliva and plasma were available.